ATE493141T1 - Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns - Google Patents

Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns

Info

Publication number
ATE493141T1
ATE493141T1 AT03010945T AT03010945T ATE493141T1 AT E493141 T1 ATE493141 T1 AT E493141T1 AT 03010945 T AT03010945 T AT 03010945T AT 03010945 T AT03010945 T AT 03010945T AT E493141 T1 ATE493141 T1 AT E493141T1
Authority
AT
Austria
Prior art keywords
morphogens
nervous system
central nervous
morphogen
ischemia
Prior art date
Application number
AT03010945T
Other languages
English (en)
Inventor
Marc F Charette
Seth P Finklestein
Original Assignee
Stryker Corp
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24485972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE493141(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Stryker Corp, Gen Hospital Corp filed Critical Stryker Corp
Application granted granted Critical
Publication of ATE493141T1 publication Critical patent/ATE493141T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Control Of Electric Motors In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Protection Of Generators And Motors (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
AT03010945T 1996-03-22 1997-03-21 Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns ATE493141T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62044496A 1996-03-22 1996-03-22

Publications (1)

Publication Number Publication Date
ATE493141T1 true ATE493141T1 (de) 2011-01-15

Family

ID=24485972

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03010945T ATE493141T1 (de) 1996-03-22 1997-03-21 Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns
AT97917532T ATE244574T1 (de) 1996-03-22 1997-03-21 Verfahren zur verbesserten funktionelle erholung der motorische koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97917532T ATE244574T1 (de) 1996-03-22 1997-03-21 Verfahren zur verbesserten funktionelle erholung der motorische koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns

Country Status (11)

Country Link
US (4) US6407060B1 (de)
EP (3) EP1364655B1 (de)
JP (2) JP2000507939A (de)
KR (1) KR20000064752A (de)
CN (1) CN1181885C (de)
AT (2) ATE493141T1 (de)
AU (2) AU734312B2 (de)
CA (2) CA2249368A1 (de)
DE (2) DE69723429T3 (de)
ES (1) ES2201287T5 (de)
WO (2) WO1997034618A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
BR9406715A (pt) 1993-05-12 1996-02-06 Genetics Inst Molécula de DNA isolada célula hospedeira vetor método para produzir uma proteina (BMP-11) polipeptideo de proteina-11 morfogenética de osso purificada (BMP-11) e molécula de DNA quimérica
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
DE69434651T2 (de) 1993-12-07 2007-03-08 Genetics Institute, Inc., Cambridge Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
AU5244998A (en) * 1996-11-15 1998-06-03 Creative Biomolecules, Inc. Morphogen-induced regeneration of sense perceptory tissues
WO1998050060A1 (en) 1997-05-05 1998-11-12 Creative Biomolecules, Inc. Therapies for acute renal failure
CA2291514C (en) * 1997-05-30 2011-07-12 Mariel Therapeutics, Inc. Methods for evaluating tissue morphogenesis and activity
CA2314423A1 (en) * 1997-12-04 1999-06-10 Creative Biomolecules, Inc. Maintenance of smooth muscle integrity by morphogenic proteins
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
DE19837230A1 (de) * 1998-08-17 2000-03-09 Jean Krutmann Neurotrophin-4 zur Behandlung von Tumoren neuroektodermalen Ursprungs
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
US6749850B1 (en) 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
BR0013388A (pt) * 1999-08-18 2002-08-27 Gen Hospital Corp Processos, composições e kits para promover a recuperação de lesões do sistema nervoso central
PT1223990E (pt) 1999-10-15 2004-12-31 Fidia Advanced Biopolymers Srl Formulacoes de acido hialuronico para administracao de proteinas osteogenicas
US7060676B2 (en) 1999-12-20 2006-06-13 Trustees Of Tufts College T. cruzi-derived neurotrophic agents and methods of use therefor
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
AU2001268147B2 (en) * 2000-06-01 2006-05-04 Children's Medical Center Corporation Methods and compositions for producing a neurosalutary effect in a subject
US6855690B2 (en) 2000-06-01 2005-02-15 Children's Medical Center Corporation Methods and compositions for treating ocular disorders
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
EP1399023B1 (de) 2001-06-01 2008-04-30 Wyeth Zusammensetzungen für die systemische verabreichung von sequenzen, die für knochenmorphogenese-proteinen kodieren
JP2004528042A (ja) * 2001-06-01 2004-09-16 エクサイト セラピーズ， インコーポレイテッド Ｔ細胞誘導性組織修復および再生
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
US20060259014A1 (en) 2002-05-22 2006-11-16 Surgimark, Inc. Aspirator sleeve and suction handle
US20040229292A1 (en) * 2002-11-26 2004-11-18 Sebastiano Cavallaro Use of FGF-18 in the diagnosis and treatment of memory disorders
AU2003297583B2 (en) 2002-11-26 2010-01-14 Biocon, Ltd Modified naturetic compounds, conjugates, and uses thereof
EP1623017B1 (de) 2003-05-08 2010-09-15 Life Technologies Corporation Erzeugung und isolierung antigenspezifischer t-zellen
JP4971149B2 (ja) 2004-06-17 2012-07-11 スラソス セラピューティックス インコーポレーテッド Ｔｄｆ関連化合物およびその類似体
EP2453024B1 (de) * 2004-06-21 2017-12-06 The Board of Trustees of The Leland Stanford Junior University Differenziell exprimierte Gene und Leitungsbahnen bei bipolarer Störung und/oder schwerer depressiver Erkrankung
WO2006012365A2 (en) * 2004-07-20 2006-02-02 University Of Maryland Protease inhibitor
WO2006011600A1 (ja) * 2004-07-29 2006-02-02 Anges Mg, Inc. 脳機能改善のための医薬および方法
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
GB0425625D0 (en) * 2004-11-22 2004-12-22 Royal College Of Surgeons Ie Treatment of disease
US8299212B2 (en) 2005-09-20 2012-10-30 Thrasos Therapeutics, Inc. TDF-related compounds and analogs thereof, analogs and bioactive fragments
CA2629299C (en) 2005-11-12 2017-08-22 The Board Of Trustees Of The Leland Stanford Junior University Fgf2-related methods for diagnosing and treating depression
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
DK2121142T3 (da) * 2007-01-25 2013-07-29 Bioph Biotech Entw Pharm Gmbh Anvendelse af GDF-5 til forbedring eller vedligeholdelse af hudens udseende
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
CN101801405A (zh) 2007-08-07 2010-08-11 先进科技及再生医学有限责任公司 包含于酸性水溶液中的gdf-5的蛋白质配方
BRPI0911048A2 (pt) * 2008-04-14 2015-12-29 Atrm Llc formulações líquidas tamponadas de gdf-5
WO2010093925A2 (en) * 2009-02-12 2010-08-19 Stryker Corporation PERIPHERAL ADMINISTRATION OF PROTEINS INCLUDING TGF-β SUPERFAMILY MEMBERS FOR TREATMENT OF SYSTEMIC DISORDERS AND DISEASE
SG173634A1 (en) * 2009-02-12 2011-09-29 Stryker Corp COMPOSITIONS AND METHODS FOR MINIMALLY-INVASIVE SYSTEMIC DELIVERY OF PROTEINS INCLUDING TGF-ß SUPERFAMILY MEMBERS
WO2010103070A2 (en) 2009-03-12 2010-09-16 Charité - Universitätsmedizin Berlin Bone morphogenetic protein 2 (bmp2) variants with reduced bmp antagonist sensitivity
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
EP2352750B1 (de) 2009-09-17 2012-06-13 Stryker Corporation Puffer zur steuerung des ph-wertes knochenmorphogenetischer proteine
WO2011087768A1 (en) 2009-12-22 2011-07-21 Stryker Corporation Bmp-7 variants with reduced immunogenicity
CN101822815A (zh) * 2010-04-29 2010-09-08 广东八加一医药有限公司 系列多肽小分子在制备防治缺血性脑血管疾病药物中的应用
PH12013500294A1 (en) 2010-08-20 2017-08-23 Wyeth Llc Designer osteogenic proteins
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
EP2801377B1 (de) 2011-03-04 2019-08-07 The Regents of The University of California Hydrogel enthaltend Zellen zur lokalen Freisetzung von Wachstumsfaktoren zur Rückgewinnung der Bewegungsfähigkeit nach einem Schlaganfall
KR101274930B1 (ko) * 2011-06-03 2013-06-17 전남대학교산학협력단 골 형성 또는 혈관신생 촉진용 펩타이드 ｂｆｐ 4 및 이의 용도
EP2734220A4 (de) * 2011-07-19 2015-01-21 Thrasos Innovation Inc Antifibrotische peptide und ihre verwendung bei verfahren zur behandlung von durch fibrose charakterisierten krankheiten und leiden
EP2784083A1 (de) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Knochenmorphogenetische Protein (BMP)-Varianten mit hoch reduzierter Antagonisten-Sensibilität und erweiterter spezifischer biologischer Aktivität
HRP20251426T1 (hr) 2013-05-06 2026-01-02 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
EP3881859B1 (de) * 2013-06-11 2024-03-06 President and Fellows of Harvard College Zusammensetzungen zur erhöhung der neurogenese und angiogenese
JP7199809B2 (ja) 2015-02-13 2023-01-06 ファクター バイオサイエンス インコーポレイテッド 核酸製品及びその投与方法
US10576167B2 (en) 2016-08-17 2020-03-03 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
BR112021000018A2 (pt) * 2018-07-03 2021-07-06 Venturis Therapeutics Inc composições e métodos para tratamento de acidente vascular cerebral
JP7791093B2 (ja) * 2020-02-20 2025-12-23 ユニベルシテイト マーストリヒト 循環ｂｍｐ１０（骨形成タンパク質１０）の検出方法
WO2021236824A1 (en) * 2020-05-19 2021-11-25 Elevian, Inc. Methods and compositions for treating stroke
EP4728052A1 (de) * 2023-06-13 2026-04-22 Bedford Research Foundation Systeme und verfahren für zelltransport bei umgebungstemperatur

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440860A (en) 1980-01-18 1984-04-03 The Children's Medical Center Corporation Stimulating cell growth
US4378347A (en) * 1980-06-30 1983-03-29 Franco Wayne P Composition for treating the heart for myocardial infarction
US4296100A (en) 1980-06-30 1981-10-20 Franco Wayne P Method of treating the heart for myocardial infarction
DE3110560A1 (de) 1981-03-18 1982-10-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen "angiotropine der leukozyten und des entzuendungsgewebes: eine neue klasse natuerlicher chemotropischer mitogene fuer das richtungswachstum von blutgefaessen und zur neovaskularisierung von geweben"
DE3382562D1 (de) 1982-09-24 1992-06-25 Us Health Wiederherstellung von gewebe bei tieren.
US4806523A (en) 1985-08-06 1989-02-21 Collagen Corporation Method of treating inflammation
US4971952A (en) 1986-03-06 1990-11-20 Collagen Corporation Method of treating inflammation with cartilage inducing factor
US4994559A (en) * 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
CA1322714C (en) 1986-11-14 1993-10-05 Harry N. Antoniades Wound healing and bone regeneration
EP0269408A3 (de) 1986-11-26 1989-08-30 Genentech, Inc. TGF-Beta für die Behandlung von entzündlichen Erkrankungen
US4797277A (en) 1987-09-22 1989-01-10 Pharmacia Ab Method for reperfusion therapy
US5108753A (en) 1988-04-08 1992-04-28 Creative Biomolecules Osteogenic devices
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
JPH0262829A (ja) 1988-05-18 1990-03-02 Nippon Kayaku Co Ltd 虚血に基づく傷害の予防及び治療剤
US4983581A (en) 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β
HU201095B (en) 1988-06-14 1990-09-28 Richter Gedeon Vegyeszet New peptides inhibiting the activity of the immune system and pharmaceutical compositions comprising same, as well as process for producing these peptides and compositions
JPH03505669A (ja) 1988-07-08 1991-12-12 ユニバーシテイ・カレツジ・ロンドン バイオアツセイにおける改良
WO1990000900A1 (en) 1988-07-20 1990-02-08 Amgen Inc. Method of treating inflammatory disorders by reducing phagocyte activation
US5057494A (en) 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
US5106626A (en) 1988-10-11 1992-04-21 International Genetic Engineering, Inc. Osteogenic factors
US5135915A (en) 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
US5011914A (en) 1989-01-05 1991-04-30 Collins Franklin D Purified ciliary neurotrophic factor
US5002965A (en) 1989-05-09 1991-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Use of ginkgolides to prevent reperfusion injury in organ transplantation
US5118791A (en) 1989-05-25 1992-06-02 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
IL97365A0 (en) * 1991-02-27 1992-05-25 Yeda Res & Dev Pharmaceutical compositions comprising a lymphokine
US5158934A (en) 1989-09-01 1992-10-27 Genentech, Inc. Method of inducing bone growth using TGF-β
WO1991005802A1 (en) 1989-10-17 1991-05-02 Creative Biomolecules, Inc. Osteogenic devices
US5108989A (en) 1990-04-04 1992-04-28 Genentech, Inc. Method of predisposing mammals to accelerated tissue repair
JPH06500466A (ja) 1990-06-15 1994-01-20 カーネギー インスチチューション オブ ワシントン Ｇｄｆ―１
EP0550625B1 (de) 1990-09-26 2003-11-05 Genetics Institute, LLC Bmp-5-derivate
EP0643767B1 (de) 1990-10-18 1998-07-22 Stryker Corporation Osteogene peptide
AU660635B2 (en) 1990-11-16 1995-07-06 Celtrix Pharmaceuticals, Inc. A beta-type transforming growth factor
CA2097063C (en) 1990-11-27 2006-08-08 Howard P. Greisler Tissue sealant and growth factor containing compositions that promote accelerated wound healing
EP0513334A4 (en) 1990-11-30 1993-08-04 Celtrix Laboratories, Inc. Use of a bone morphogenetic protein in synergistic combination with tgf--g(b) for bone repair
WO1992015323A1 (en) 1991-03-11 1992-09-17 Creative Biomolecules, Inc. Protein-induced morphogenesis
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
JPH06500574A (ja) 1991-05-10 1994-01-20 ザ　ソーク　インスティテュート　フォア　バイオロジカル　スタディーズ アクチビン／ＴＧＦ―βスーパーファミリーのレセプターのクローニングおよび組換えによる産生
JPH07500315A (ja) 1991-05-10 1995-01-12 セルトリックス　ファーマシューティカルズ，インコーポレイテッド 骨成長因子の標的送達
WO1993000050A1 (en) 1991-06-21 1993-01-07 Genetics Institute, Inc. Pharmaceutical formulations of osteogenic proteins
AU652472B2 (en) 1991-06-25 1994-08-25 Genetics Institute, Llc BMP-9 compositions
EP0601129B1 (de) 1991-08-30 2000-11-15 Creative Biomolecules, Inc. Screeningverfahren von morphogenischen Proteinen
DE69233559T2 (de) 1991-08-30 2006-08-31 Curis, Inc., Cambridge Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten
ATE192931T1 (de) * 1991-08-30 2000-06-15 Creative Biomolecules Inc Morphogen-induzierte modulation von entzündlichen antworten
ATE238417T1 (de) 1991-11-04 2003-05-15 Inst Genetics Llc Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung
WO1993008828A1 (en) * 1991-11-08 1993-05-13 Syntex-Synergen Neuroscience Joint Venture Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
DE69228949T2 (de) 1991-11-22 1999-09-16 Auckland Uniservices Ltd., Auckland Tgf-beta zur verbesserung der regeneration von neuronalem gewebe
DE19525416A1 (de) † 1995-07-12 1997-01-16 Bioph Biotech Entw Pharm Gmbh Verwendung von MP52 zur Behandlung und Prävention von Erkrankungen des Nervensystems
EP0653942B2 (de) 1992-07-31 2007-03-07 Curis, Inc. Morphogen induzierte nerven wiederherstellung und wiedergutmachung.
ES2061380B1 (es) * 1992-11-23 1995-07-01 Boehringer Ingelheim Espana Empleo del factor de crecimiento fibroblastico y sus derivados como neuroprotectores y neuromoduladores.
DK0716610T3 (da) 1993-08-26 2006-09-04 Genetics Inst Llc Humane knogle-morfogenetiske proteiner til anvendelse ved neural regenerering
AU7605394A (en) 1993-09-03 1995-03-22 Regents Of The University Of California, The Neural tissue affecting factor and compositions
DE69434934D1 (de) 1993-10-14 2007-04-12 Harvard College Verfahren zur induzierung und zur erhaltung neuronalen zellen
AU6787594A (en) 1994-03-10 1995-09-25 Human Genome Sciences, Inc. Bone morphogenic protein-10
AU5244998A (en) * 1996-11-15 1998-06-03 Creative Biomolecules, Inc. Morphogen-induced regeneration of sense perceptory tissues

Also Published As

Publication number Publication date
EP0904093A1 (de) 1999-03-31
CN1219133A (zh) 1999-06-09
CN1181885C (zh) 2004-12-29
EP1364655B1 (de) 2010-12-29
DE69740089D1 (de) 2011-02-10
US20010039261A1 (en) 2001-11-08
EP1364655A1 (de) 2003-11-26
US20030022830A1 (en) 2003-01-30
JP2000507939A (ja) 2000-06-27
CA2249368A1 (en) 1997-09-25
EP0894004B2 (de) 2007-02-21
AU734312B2 (en) 2001-06-07
ES2201287T3 (es) 2004-03-16
JP4847634B2 (ja) 2011-12-28
DE69723429T2 (de) 2004-04-22
US6214796B1 (en) 2001-04-10
WO1997034626A1 (en) 1997-09-25
DE69723429D1 (de) 2003-08-14
ES2201287T5 (es) 2007-10-16
EP0894004A1 (de) 1999-02-03
ATE244574T1 (de) 2003-07-15
CA2249596C (en) 2011-11-08
US6407060B1 (en) 2002-06-18
JP2000506894A (ja) 2000-06-06
AU2552997A (en) 1997-10-10
EP0904093A4 (de) 2004-11-17
KR20000064752A (ko) 2000-11-06
AU725341B2 (en) 2000-10-12
DE69723429T3 (de) 2007-09-20
WO1997034618A1 (en) 1997-09-25
CA2249596A1 (en) 1997-09-25
AU2582397A (en) 1997-10-10
EP0894004B1 (de) 2003-07-09

Similar Documents

Publication Publication Date Title
ATE493141T1 (de) Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns
DE3587266D1 (de) Verfahren und system zur entfernung von immunosuppressiven bestandteilen aus saeugetierblut.
DE69532482D1 (de) Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda-antagonisten enthält
ATE140388T1 (de) Zusammensetzungen enthaltend omega conotoxin peptide derivate und deren verwendung zur behandlung von ischämie-artigen neuronalen schädigungen
ATE293883T1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
EP0464932A3 (en) Inhibition of wasting and protein degradation of mammalian muscle by tetracyclines
DE69232287D1 (de) Verfahren und zusammensetzung zur verminderung von reperfusionsschäden des myokards
IL91322A0 (en) Acid-resistant fgf composition and method of treating ulcerating diseases of the gastrointestinal tract
DE3878627D1 (de) Zusammensetzung zur oberflaechenbehandlung von kautschuk.
DE69316013D1 (de) Verwendung von phosphinate zur behandlung der osteoporose
DE69638281D1 (de) Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen
ATE526980T1 (de) Zusammensetzungen und verfahren zur heilung von nervengeweben
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
EP0515434A4 (en) Method for treating intestinal diseases
DE69431199D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
ATE118350T1 (de) Zusammensetzungen und verfahren zur behandlung von hautkrankheiten und zur aktivierung der wundheilung.
DE69924483D1 (de) Kombinationstherapie zur behandlung von tumoren
EP0435177A3 (en) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
BG102716A (en) Method for the treatment of cardiac insufficiency by means of formulations opposing the endotheline
ATE167628T1 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion
GR3017358T3 (en) 5-Aryl-3H-1,2,4-triazol-3-ones and their use as anticonvulsants.
Baines et al. Selective activity of a proctolin analogue reveals the existence of two receptor subtypes
UA39179C2 (uk) Фармацевтична композиція для лікування порушень серцевого ритму у великих ссавців та людей, спосіб її одержання та антиаритмічний лікарський засіб
EP0116628A4 (de) 1-acyl-3-pyridylmethylguanidine und deren verwendung als antihypertensiva.
DE3479477D1 (en) A pharmaceutical composition for use in treating neurological disease or aging

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties